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 Cancer is the leading cause of death in humans and dogs in Japan. 
Up to the present date, a great deal of clinical examination and therapy of 
cancer has been investigated. In particular, early detection and treatment 
of cancer are recognized as important challenges. Recently, analysis of 
plasma free amino acids (PFAAs) using liquid chromatography-mass 
spectrometry (LC/MS) had been developed in human medicine. PFAAs 
enables risk assessment of multiple types of cancer with only one blood 
sampling. However, PFAAs have not ever been clinically applied in 
veterinary medicine. Furthermore, there are few studies investigating the 
relationship between cancer and PFAAs using an exhaustive analysis. 
Purpose of the current study was to investigate the changes in PFAAs in 
dogs with cancer and to obtain new findings showing the relationship 
between cancer and PFAAs. 
 
We evaluated accuracy and reproducibility of PFAAs using LC/MS 
in dogs, and excellent accuracy and reproducibility were confirmed. 
Dietary effects were not observed in PFAAs after postprandial 14 hours. 
Furthermore, different daily fluctuation between daytime and nighttime 
was observed in some kinds of PFAAs. We recommend that dogs should be 
fasted over 14 hours, and blood sampling for PFAAs measurement should 
be performed in the morning. And the assay should be made as soon as 
possible after blood collection. Some PFAAs, such as Glycine, which would 
be consumed in energy production processes, significantly decreased in 
cancer dogs. The PFAAs that decreased in cancer dogs might be ingested 
by cancer cells aggressively, and the PFAAs that increased might be 
produced by protein catabolism, but not used in cancer cells, or produced 
in cancer cells and secreted into circulation. Significant increase in some 
PFAAs related to skeletal muscle metabolism might reflect catabolism of 
muscle proteins in cancer dogs. In addition, we investigated the difference 
in PFAAs with each type of cancer. Isoleucine was significantly lower in 
thyroid cancer and significantly higher in hepatocellular carcinoma. Thus, 
different PFAAs profiles were observed in different types of cancer. Finally, 
we investigated the change of PFAAs after chemotherapy in dogs, focusing 
on transitional cell carcinoma (TCC), because chemotherapy is 
recommended as treatment of TCC. Significant changes were observed in 
mean plasma Cystathionine concentrations between before and after 
chemotherapy. It was suggested that PFAAs is affected by administration 
of anticancer drugs.  
In conclusion, we have performed an exhaustive measurement of 
PFAAs with different types of cancer and their changes before and after 
chemotherapy in dogs. We obtained new findings on the relationship 
between cancer and PFAAs in dogs. The results indicates that the PFAAs 
assay is useful for early detection and risk assessment of cancer, and the 
monitoring of treatment in dogs. 
